Trial reportPain research & management2026
Ultrasound-Guided Stellate Ganglion Block in Fibromyalgia: A Randomized, Single-Center, Single-Blind, Sham-Controlled Trial.
Trial report in Pain research & management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07343128 (Ultrasound-Guided Stellate Ganglion Block in Fibromyalgia), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Ultrasound-Guided Stellate Ganglion Block in Fibromyalgia: A Randomized, Single-Center, Single-Blind, Sham-Controlled Trial
Who cites it
1 citing paper in PubMed.
- Ultrasound-Guided Stellate Ganglion Block in Fibromyalgia: A Randomized, Single-Center, Single-Blind, Sham-Controlled Trial.Pain research & management · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFibromyalgia is a chronic pain syndrome characterized by widespread pain, fatigue, and sleep disturbance. Many patients remain symptomatic despite guideline-concordant pharmacologic therapy. Stellate ganglion block (SGB) modulates sympathetic activity and may provide an adjunctive option for fibromyalgia-related pain.
methodsIn this single-center, randomized, single-blind, sham-controlled trial, adults fulfilling the 2016 American College of Rheumatology criteria and receiving stable duloxetine 60 mg/day were randomized 1:1 to ultrasound-guided SGB or a sham procedure. Two procedures were performed 1 week apart. The primary endpoint was change in the Fibromyalgia Impact Questionnaire Revised (FIQR) total score from baseline to 1 week. Secondary endpoints included FIQR change at 1 month, pain intensity on an 11-point Numerical Rating Scale (NRS), and FIQR responder rates (≥ 30% and ≥ 50% improvement). Primary analyses were per-protocol (n = 60), with modified intention-to-treat (mITT, n = 60) and last observation carried forward (LOCF, n = 68) sensitivity analyses. ANCOVA was adjusted for baseline FIQR.
resultsOf 108 screened patients, 68 were randomized (SGB n = 33; control n = 35); 60 (30 per group) completed all assessments. Baseline FIQR was 87.7 ± 7.1 in the SGB group and 82.0 ± 11.3 in controls. At 1 week, FIQR decreased to 53.4 ± 19.0 with SGB versus 77.2 ± 16.3 with control; at 1 month, FIQR was 63.1 ± 20.3 versus 80.2 ± 10.7, respectively. ANCOVA-adjusted between-group differences in FIQR change favored SGB by -29.9 points (95% CI -37.9 to -21.9; p < 0.001) at 1 week and -22.9 points (95% CI -30.1 to -15.7; p < 0.001) at 1 month. NRS pain reductions were also significantly greater with SGB at both time points (adjusted difference -3.1 points, 95% CI -4.1 to -2.0, p < 0.001 at 1 week; -2.6 points, 95% CI -3.6 to -1.6, p < 0.001 at 1 month). No serious complications occurred; adverse events were transient and mild.
conclusionIn treatment-resistant fibromyalgia patients receiving stable duloxetine, ultrasound-guided SGB produced clinically meaningful short-term improvements in fibromyalgia impact and pain with an acceptable safety profile. However, the large effect sizes should be interpreted cautiously given potential unblinding and placebo effects. Larger, multicenter trials with longer follow-up, objective outcome measures, and formal blinding assessment are warranted.
trial registrationClinicalTrials.gov Identifier: NCT07343128.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.